

**OMTO, Volume 25**

**Supplemental information**


**IFNAR blockade synergizes with oncolytic**

**VSV to prevent virus-mediated PD-L1**


**expression and promote antitumor T cell activity**

**Nader El-Sayes, Scott Walsh, Alyssa Vito, Amir Reihani, Kjetil Ask, Yonghong Wan, and Karen Mossman**






**Figure S3.** Type I IFN induces IFIT1 upregulation. **(A)** MC38 and **(B)** B16F10 parental and IFNAR knockout cells and were treated with 100 U/mL of IFN $\alpha$  or IFN $\beta$ . RNA was harvested and used to assess mRNA expression of IFIT1 via RT-PCR.




**Figure S4.** Validation of VSV initiation of replication. (A) MC38 and B16F10 parental and IFNAR knockout cells were infected with VSV $\Delta$ 51-GFP at MOI 1 for 8, 16 and 24 hours then imaged using a fluorescence microscope. B16F10 parental and IFNAR knockout cells were infected with VSV $\Delta$ 51-GFP at MOI 1 for 24 hours then GFP fluorescence was measured by flow

cytometry. **(B)** Representative histogram and **(C)** MFIs of GFP expression in B16F10 parental and IFNAR ko cells 24 hours post infection. **(D)** MC38 parental/IFNAR ko cells were infected with VSVΔ51-GFP at MOI 1 for 24 hours then viability was measured by flow cytometry.



**Figure S5.** Gating strategy used to characterize different leukocytes from PBMCs to assess PD-L1 surface expression (corresponds to data from Figure 5).



**Figure S6.** Gating strategy used to characterize T cells from PBMCs (corresponds to data from Figure 6).